STANDARD BIOTOOLS INC. Revenue From Contract With Customer Excluding Assessed Tax

• STANDARD BIOTOOLS INC. showed a decrease of -6.2% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
• This data is from STANDARD BIOTOOLS INC.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2017: $25.53 million | Q2 2017: $23.91 million | Q3 2017: $24.75 million | Q4 2017: $27.75 million | Q1 2018: $25.25 million | Q2 2018: $26.43 million | Q3 2018: $28.96 million | Q4 2018: $32.33 million | Q1 2019: $30.11 million | Q2 2019: $28.20 million | Q3 2019: $26.50 million | Q4 2019: $32.44 million | Q1 2020: $27.62 million | Q2 2020: $26.06 million | Q3 2020: $39.86 million | Q4 2020: $44.61 million | Q1 2021: $32.79 million | Q2 2021: $31.02 million | Q3 2021: $28.50 million | Q1 2022: $26.50 million | Q2 2022: $18.78 million | Q3 2022: $25.65 million | Q1 2023: $25.12 million | Q2 2023: $27.67 million | Q3 2023: $25.37 million | Q1 2024: $45.54 million | Q2 2024: $22.49 million | Q3 2024: $22.09 million | Q1 2025: $40.80 million | Q2 2025: $21.76 million | Q3 2025: $19.55 million.
• Over the full 10 years of available data (2016 to 2025), STANDARD BIOTOOLS INC.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 18.3%.
• Historical annual values: Fiscal year 2025: $85.33 million | Fiscal year 2024: $91.01 million | Fiscal year 2023: $106.34 million | Fiscal year 2022: $97.95 million | Fiscal year 2021: $130.58 million | Fiscal year 2020: $138.14 million | Fiscal year 2019: $117.24 million | Fiscal year 2018: $112.96 million | Fiscal year 2017: $101.94 million | Fiscal year 2016: $104.45 million.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026